Protect Your Little One from RSV with Monoclonal Antibody RSV Prevention for newborns and infants

Effectiveness of Monoclonal Antibody for RSV Prevention (Nirsevimab) in Infants:

• Reduces the risk of RSV infection by up to 79.5%
• Lowers the risk of hospitalization due to lower respiratory tract infection from RSV by up to 83.2%
• Decreases ICU ventilator use by 75.3%
• Provides protection for up to 5 months, covering the peak RSV season

Contraindications for Monoclonal Antibody for RSV Prevention (Nirsevimab)

Do not administer the monoclonal antibody for RSV prevention to children with a history of severe allergic reactions to Nirsevimab or its components, such as arginine or histidine.

Additional Notes:

• Monoclonal antibody for RSV prevention is important for building immunity in infants during their first year of life
• Infants aged 0–2 years with underlying health conditions are eligible to receive the injection
• It can be administered alongside routine childhood vaccines without the need to space them out—even with live vaccines, as it does not interfere with vaccine-induced immunity.
• Monoclonal antibody for RSV prevention can be given at the same time as other vaccines, as long as each is injected at a different site.